Currently, the assessment of downregulation of oncogenic receptors in response to targeted therapy is limited by ex-vivo tests of biopsied tissues, anatomic or metabolic comparison of disease progression before and after a complete therapeutic cycle. Optimization of the treatment would greatly benefit from a real-time in-vivo assessment of the expression of the targeted biomarkers during the treatment and especially at the early stages of the therapy.
Introduction
Detection of specific oncogenic biomarkers is one of the most important requirements for choosing the proper type of targeted cancer therapy. Development of the drugs, targeting specific tumor receptors, such as monoclonal antibodies (mAb), has opened exciting opportunities to selectively attack the cancer-causing biomarkers, inactivate molecular mechanisms responsible for cell malignancy, and deliver the toxin specifically to the malignant cells (1-5). Recent advances in therapeutic mAb show that their efficacy depends strongly on the expression of tumor-specific biomarkers. Meanwhile, currently, the effectiveness of therapy is generally assessed either by ex-vivo tests of biopsied tissues, anatomic (e.g. CT, MRI) or metabolic (FDG-PET) comparison of disease progression before and after a complete therapeutic cycle. There is a huge demand for monitoring the effect of the drug on cancer biomarkers during the therapeutic cycles to evaluate the patient response to the therapy and optimize the course of the treatment, especially at its early stages.
Current diagnostic gold standards for detection of specific cancer biomarkers are all based on exvivo methods, such as immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH).
All these semi-quantitative methods are invasive and require biopsies from the patients (6).
Inherently, diagnostic value of biopsies is limited by the heterogeneity of the malignant lesion (see, for example, the case of Human Epidermal Growth Factor 2 (HER2) distribution for N87 tumor in Fig. 1 ). In addition, the number of times that the biopsy can be taken during the therapeutic cycle is small; therefore it can hardly be used to monitor the therapeutic outcome.
The general goal is to replace current methods with a minimally invasive imaging modality, reducing the time between imaging and diagnosis, and facilitate analysis of treatment progression in the clinic with portable and accessible systems. Molecular imaging, using targeted 5 probes (7-11), can be used to assess the status of specific cancer receptors in-vivo and differentiate the malignant lesions based on their molecular specifications. This can be realized either with positron emission tomography (PET) (12, 13) or optical imaging (14) (15) (16) . Though optical modality is limited by tissue penetration depth (in near infrared (NIR) region up to several cm), it is a minimally invasive, low cost modality without ionizing radiation. It is best suited for clinical applications such as non-invasive imaging of breast, head/neck, and skin cancer or finding the tumor and its margins during the surgery (17) ; and it can be extended for different oncogenic receptors (16) . Optical imaging can benefit from using different colors of fluorescence proteins (10, 11) and/or exogenous targeted fluorescent probes (18) simultaneously to observe different receptors in cancer cells. High quantum yield NIR fluorescent dyes can be conjugated with high affinity targeted molecular probes (19, 20) and combined with fluorescence imaging and mathematical models for data analysis to create a platform for a new "image and treat paradigm". In pre-clinical studies (small animal models), NIR imaging, using biomarkerspecific probes, can be applied for screening and testing the efficacy of different therapies/drugs to treat various cancers (15) .
Due to the leaky vascularization of the tumor and its Enhanced Permeability and Retention (EPR) effect, using fluorescence intensity alone has limitations (21, 22) . It is difficult to establish that the detected fluorescence intensity originates from the bound targeted fluorescent agents to specific cancer receptor or it comes from accumulated free fluorophores inside the tumor due to its EPR effect and leaky vascularization. On the other hand, even though fluorescence intensity based imaging methods have been successfully applied for analysis of some biomarkers in vivo (23) (24) (25) (26) , to be quantitative they require sequences of images at different time points to separate bound and unbound fluorophores and use pharmacokinetics of fluorescence intensity to take into account the accumulation and washout of the probe from blood circulation.
Fluorescence lifetime imaging is an alternative non-invasive in-vivo imaging approach, based on the time-resolved fluorescence data collection after a short excitation laser impulse. It maps the exponential decay rates (i.e. lifetime) of the fluorescence signal (27, 28) . Florescence lifetime imaging can take advantage of environmental sensitivity of fluorescent contrast agents (e.g. to temperature or pH) and/or their interaction with other molecules (e.g. binding to cancer cell receptors) without dependence on dye concentration in tissues. This phenomenon is unique in optical imaging and can provide significant benefit relative to intensity-based methods including both optical and nuclear imaging. Here we pursue the latest possibility to relate the fluorescence lifetime with binding of the HER2-specific fluorescent contrast agent to HER2 receptors. From only one time point measurement after probe injection (which is more convenient for patients in clinic), fluorescence lifetime can evaluate the fraction of bound to total fluorescent probes in the tumor in vivo to separate high and low HER2 expression tumors (29) and follow the efficacy of targeted therapy. In addition, using other types of probes (e.g. pH sensitive dye), it can provide valuable information on cancer cell environment and characteristics of its abnormalities (30, 31) .
In this study, we investigated the feasibility of fluorescence lifetime imaging to monitor in-vivo expression of the HER2 receptor in the breast carcinoma (mouse model) during the course of treatment. Amplification of HER2 gene and overexpression of HER2 receptor has been diagnosed in approximately 20% of invasive breast cancer cases (32) . It is one of the most important factors in poor prognosis and resistance to traditional chemotherapy treatments in cancer patients (32, 33 In our previous study (29) , we showed that fluorescence lifetime can be used for a preliminary assessment of HER2 expression in tumor. We have observed in-vivo that binding of the In this study, we investigated the relation between the efficacy of the HER2-targeting treatment and the fluorescence lifetime. In these experiments, we used a HER2-Affibody fused to albumin binding domain (ABD) that has been described before (26) . This dimmer Affibody probe shows high affinity to the receptor and stays longer in the blood. The results show that the difference between the fluorescence lifetime at the tumor and contralateral site has a good correlation with the treatment outcome and it can be used as early indicator of HER2 downregulation due to the treatment.
Materials and Methods
HER2 targeted contrast agent and therapeutic agent. In these studies, the HER2-specific We prepared working cell banks (usually around 10 vials) from each cell vial with the use of recommended culture media. The cell lines were used within 6 months after received from cell banks. Quality control and authentication procedures that were conducted with ATCC includes post freeze viability, growth properties, morphology, mycoplasma using the Hoechst DNA stain (indirect method) and agar culture (direct method). They also performed the species determination test using isoenzyme assay for interspecies and STR analysis (unique DNA profile).
The cells were grown in RPMI culture media supplemented with 10% fetal bovine serum (FBS) and Pen/Strep (10,000 U penicillin, 10 mg streptomycin) at 37°C and 5% CO 2 in a humidified incubator. Solution of 0.05% trypsin and 0.02% EDTA was used for cells detachment. 
the tissue surfaces to produce a real-time, two-dimensional image of the ROI. A cooled, chargecoupled device (CCD) camera is used to locate the tumor and guide the scanner to the ROI by measuring the fluorescence intensity distribution over the mouse body.
Before imaging, the mouse was anesthetized by isoflurane inhalation. The mouse was placed on a temperature-controlled stage and two sets of images from the tumor region and contralateral site were captured before injection. Then, 10 µg of the ABD-HER2-Affibody conjugated to Each pixel covers the intensity of 2x2 (mm 2 ), which is much smaller than the size of the tumor.
The fluorescence intensity and lifetime at tumor site and contralateral site were averaged over 6 pixels and 16 pixels, respectively to reduce the effect of noise. 
Results
The fluorescence signal at the tumor and contralateral sites were captured continuously every 3 hours for the first 16 hours after injection of ABD-HER2-Affibody conjugated to AlexaFluor 750. We observed very stable values of the fluorescence lifetime at the contralateral site, in all three groups, (before, 12 hours and 7 days after the last treatment) and over the 16 hours monitoring, while significant variations in observed fluorescence intensity between different mice and during this time range were present (due to probe washout).
As an example, Figures 2a and 2b show the lifetime at the contralateral site for two mice before the treatment. Even though, the amplitudes of the two signals were very different (fluorescence intensity in mouse #1 is 240% higher than mouse #2); their lifetime difference was less than ±1.9% at different time points. Figure 3a shows the average fluorescence lifetime at the tumor site as a function of time after the probe injection. Comparing these data with the data from contralateral site one could see that for the control group of mice (before treatment) and the mice, imaged 7 days after treatment, there is a significant difference in the lifetimes between tumor and contralateral site ~0.13 ns, which stays the same after 3 hours post probe injection (Fig. 3b) . Meanwhile, for the group of mice that was observed soon after the therapy (fluorescence probe injected 12 hours after the last injection of the drug) the average difference between fluorescence lifetime at the tumor and contralateral sites proved to be much lower slowly increasing from 0.03 ns at 3 hours after injection to 0.065 ns at 14 hours (Fig. 3b) . Figure 4 shows the fluorescence intensity and lifetime images at the tumor and contralateral site of one mouse in each group at different time points.
We also measured the tumor volume before each imaging cycle (Fig. 5) . The effect of treatment was maximal (tumor volume reduced ~2 times) at 12 hours after the last treatment with 17-DMAG, while a week later, tumor came back to almost pre-treatment dimensions, as can be seen in Figure 5 . 
Discussion
HSP90 chaperone is responsible for the properly folding of subset of proteins, including HER2, which are essential for cell signaling. Therefore, disruption of cell proliferation and apoptosis in tumors through HSP90 inhibitors (e.g. 17-DMAG) is realized by a simultaneous inhibition of multiple pathways critical for tumor survival, including the HER2 pathway (40, 41) . In relation to HER2 proteins, HSP90 not only controls the stability of the nascent form of HER2 in its maturation process in the endoplasmic reticulum, but also regulates its mature form during its residency at the plasma membrane and maintain it in a state capable for activation (42) . Tumor cells demonstrate higher HSP90 activity and lesions can accumulate more HSP90 inhibitors than normal tissues through their leaky vascularization.
It is known from the literature that application of HSP90-inhibitting drugs results in considerable downregulation of HER2 receptors soon after the course of therapy. For HER2-positive tumors (similar to mouse xenografts of human breast carcinoma BT-474, studied in this work) it was shown, using both PET and ex-vivo methods, that HER2 overexpression was considerably reduced (~ 3 times) at ~12 hours after the last 17-DMAG treatment (35) . On the other hand, in the paper (34), PET was used to follow variations in HER2 expression in mouse model after treatment with 17-AAG drug (another derivative of Geldamycin, HSP90 inhibitory component of 17-DMAG). Authors observed significant downregulation of HER2 (~3 times) at ~20 hours after the therapy was completed, while at later times (≥5 days) HER2 overexpression rapidly recovered, returning to pre-treatment level at 12 days after the therapy. It should be noted that in all these experiments the fluorescence lifetime of ABD-HER2-Affibody-based probe at the contralateral site is practically constant (0.837±0.016 ns), while the variations in the fluorescence intensity are quite significant both within different mice groups and at different measurement time points for an individual mouse (Fig. 2) . Therefore, the measurement from the contralateral site can be used, as a reference, to evaluate variations of the fluorescence lifetime at the tumor site. Low variations in the fluorescence lifetime at the contralateral site after the therapy also indicate that the effect of free 17-DMAG molecules in the circulation was not significant on fluorescence lifetime. modality compared to fluorescence intensity imaging and requires a more sophisticated instrumentation, however, the price of its main components, i.e., fast lasers (ps lasers) and fast detectors (e.g. PMT's) has been dropped significantly over the last years and gradually more time-resolved systems become commercially available, e.g., eXplore Opix (GE Medical Systems, London, ON) and ART Advanced Technologies (43) . By moving these technologies to clinic, mass production of the systems can further decrease their cost. 
